Get the Stockscreener App
227.59
0.14%
-0.44
After Hours:
228.00
0.41
+0.18%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $227.59, with a volume of 2.71M.
It is down -0.14% in the last 24 hours and up +3.22% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$228.03
Open:
$227
24h Volume:
2.71M
Relative Volume:
0.51
Market Cap:
$402.05B
Revenue:
$58.33B
Net Income/Loss:
$3.73B
P/E Ratio:
108.31
EPS:
2.1013
Net Cash Flow:
$18.24B
1W Performance:
-1.59%
1M Performance:
+3.22%
6M Performance:
+18.39%
1Y Performance:
+20.05%
1-Day Range:
$224.31
$228.40
1-Week Range:
$224.31
$232.16
52-Week Range:
$163.81
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
227.59 | 402.83B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
LLY
Lilly Eli Co
|
820.29 | 740.84B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
186.93 | 458.49B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
123.39 | 250.00B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.03 | 219.80B | 63.43B | 16.42B | 14.72B | 6.4861 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie: Deep Discount Before Earnings (NYSE:ABBV) - Seeking Alpha
Should You Buy AbbVie Stock Ahead of Q3 Earnings Report? - sharewise.com
Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM - WV News
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever. - The Motley Fool
Can AbbVie Inc. stock attract analyst upgrades2025 Year in Review & Risk Controlled Swing Trade Alerts - newser.com
Chronic Idiopathic Constipation Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment DelveInsight | ABBVIE, Eisai Co, Anji Pharma, Yuhan, Renexxion Ireland, Forest - Barchart.com
AbbVie Defends Challenge Of Colorado's Discount Drug Law - Law360
Can AbbVie Inc. stock withstand economic slowdownEarnings Overview Summary & Fast Exit and Entry Trade Guides - newser.com
Will AbbVie Inc. (Common Stock) (4AB0) stock extend growth storyPortfolio Gains Report & Free Weekly Chart Analysis and Trade Guides - Fundação Cultural do Pará
Can AbbVie Inc. stock surprise markets with earningsPortfolio Growth Summary & Real-Time Chart Pattern Alerts - newser.com
What's in Store for These 5 Pharma Bigwigs This Earnings Season? - TradingView
Will AbbVie Inc. stock attract more institutional investorsJuly 2025 Rallies & Low Drawdown Momentum Ideas - newser.com
Pigmentation Disorders Treatment Market Is Booming Worldwide 2025-2032 |Abbvie Inc., Edesa Biotech, Inc., Amgen - openPR.com
Is AbbVie Inc. stock a buy on dips2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com
Is AbbVie Inc. stock resilient to inflationJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com
Ophthalmic Drugs Market Set for Dynamic Growth with Key Players Abbvie Inc. (Allergan Plc), Alcon, Inc., Novartis AG - openPR.com
Fish Skin Disease Market to Witness Remarkable Growth With GSK - openPR.com
Will AbbVie Inc. (Common Stock) (4AB0) stock test record highs in 20252025 Top Gainers & High Yield Stock Recommendations - newser.com
How AbbVie Inc. stock performs in rising dollar environmentWeekly Earnings Recap & Daily Oversold Bounce Ideas - newser.com
How sentiment analysis helps forecast AbbVie Inc.July 2025 Movers & Comprehensive Market Scan Insights - newser.com
Why AbbVie Inc. (4AB) stock stays on top picksPortfolio Risk Summary & Technical Pattern Alert System - newser.com
How the Story for AbbVie Is Evolving After Key Pipeline Wins and Analyst Shifts - Yahoo Finance
AbbVie Stock Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com
AbbVie’s ABBV-932 Study: A New Hope for Bipolar Disorder Treatment? - TipRanks
Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It? - sharewise.com
AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth - sharewise.com
AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism - ts2.tech
Wolfe Research Adjusts AbbVie Price Target to $275 From $235, Maintains Outperform Rating - MarketScreener
United States Breast Reconstruction Market Growth Trends and Forecast Report 2025-2033, Profiles of Mentor Worldwide, AbbVie, Integra, Sientra, Stryker, Establishment Labs, RTI Surgical, TELA Bio - Yahoo Finance
How AbbVie Inc. (Common Stock) (4AB0) stock behaves under inflation pressureEarnings Summary Report & Free Weekly Chart Analysis and Trade Guides - newser.com
AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Analyst Says He Likes AbbVie (ABBV) Amid ‘Attractive’ Valuation - Insider Monkey
Will Rinvoq’s Superiority Over Humira in SELECT-SWITCH Trial Change AbbVie's (ABBV) Narrative - Yahoo Finance
AbbVie Inc. (ABBV): A Bull Case Theory - Insider Monkey
AbbVie Up More Than 30% in 6 Months: How to Play the Stock - The Globe and Mail
YieldBoost AbbVie From 2.9% To 6.9% Using Options - Nasdaq
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - Yahoo Finance
Qualcomm, Aptiv, Palo Alto And A Health Care Stock On CNBC's 'Final Trades' - Benzinga
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.78%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):